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a  b  s  t  r  a  c  t
Brucella  spp.  are  zoonotic  Gram-negative  intracellular  pathogens  with  the  ability  to  survive and  replicate
in  phagocytes.  It has been  shown  that  bacterial  proteins  expressed  abundantly  in  this  niche  are  stress-
related  proteins  capable  of triggering  effective  immune  responses.  BMEI1549  is a molecular  chaperone
designated  DnaK  that  is  expressed  under  stress  conditions  and  helps  to prevent  formation  of  protein
aggregates.  In order  to study  the  potential  of  DnaK  as a prospective  Brucella  subunit  vaccine,  immuno-
genicity  and  protective  efﬁcacy  of recombinant  DnaK  from  Brucella  melitensis  was  evaluated  in  BALB/c
mice.  The  dnak  gene  was  cloned,  expressed  in  Escherichia  coli,  and  the  resulting  recombinant  protein  used
as  subunit  vaccine.  DnaK-immunized  mice  showed  a strong  lymphocyte  proliferative  response  to  in vitro
antigen  stimulation.  Although  comparable  levels  of  antigen-speciﬁc  IgG2a  and  IgG1  were  observed  in
immunized  mice,  high  amounts  of IFN-,  IL-12  and  IL-6, no  detectable  level  of  IL-4  and  very low levels  of
IL-10  and  IL-5  were produced  by  splenocytes  of  vaccinated  mice suggesting  induction  of  a Th1  dominant
immune  response  by  DnaK.  Compared  to  control  animals,  mice vaccinated  with  DnaK  exhibited  a  signiﬁ-
cant  degree  of protection  against  subsequent  Brucella  infection  (p < 0.001),  albeit  this  protection  was  less
than the protection  conferred  by Rev.1  (p < 0.05).  A further  increase  in protection  was  observed,  when
DnaK  was combined  with  recombinant  Omp31.  Notably,  this  combination,  as  opposed  to  each  component
alone,  induced  statistically  similar  level  of  protection  as induced  by  Rev.1  suggesting  that  DnaK  could  be
viewed  as  a  promising  candidate  for the  development  of  a  subunit  vaccine  against  brucellosis.
©  2014  Elsevier  Ltd. All  rights  reserved.. Introduction
Brucella melitensis is a zoonotic Gram-negative pathogen that
s an important etiological agent causing abortion and infertil-
ty in domestic animals, and undulant fever, migratory arthralgia,
yalgia and osteomyelitis in humans [1,2]. Because of the severe
conomic and medical burden of brucellosis, vaccination of all vul-
erable hosts and culling of infected animals is the only way of
ontrolling the disease [3]. The live attenuated B. melitensis Rev.1
∗ Corresponding author at: Nanobiotechnology Research Center, AvicennaRe-
earch Institute, ACECR, Tehran, Iran PO. Box: 19615-1177.
∗∗ Corresponding author at: Monoclonal Antibody Research Center, AvicennaRe-
earch Institute, ACECR, Tehran, Iran PO. Box: 19615-1177.
E-mail addresses: Mahjed@avicenna.ac.ir (M.  Jeddi-Tehrani),
arnani@avicenna.ac.ir, zarnania@gmail.com (A.-H. Zarnani).
ttp://dx.doi.org/10.1016/j.vaccine.2014.09.013
264-410X/© 2014 Elsevier Ltd. All rights reserved.strain is the most broadly used vaccine in control programs against
brucellosis in the livestock [4]. It has been shown that Rev.1 can
be useful for eradicating this disease [5]. Thus, it is considered
in widespread vaccination programs in many countries [6]. Nev-
ertheless, availability of such vaccines as Rev.1 does not obviate
the need for development of new vaccines due to some problems
associated with application of this vaccine, included among them
are eliciting long lasting immune responses against the O polysac-
charide making it difﬁcult to differentiate vaccinated animals from
those naturally infected, induction of abortion when administered
during pregnancy, pathogenicity for humans and resistance to
streptomycin [7]. These problems have stimulated scientists to ﬁnd
alternative ways to protect the livestock from Brucella infection.
In order to increase safety, subunit vaccines have been devel-
oped but these depend on the identiﬁcation of antigens able to
confer protection against brucellosis. Numerous protein antigens
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re shown to stimulate protective immune response in mice model.
he recent examples comprise HspA [8], ribosomal protein L9 [9],
LSOmp31 [10], rF278a [11], FlgJ and FliN [12], Omp31, Omp16
nd BP26 expressed by invasive Escherichia coli vaccines [7], CobB
nd AsnC [13], Omp28 formulated with CpG oligonucleotides [14],
39 protein formulated with CpG oligodeoxynucleotides [15], Ado-
cyase [16] and Rs- [17], combination of Omp16 and Omp19 [18].
lthough some of these antigens have been recently identiﬁed, the
rotection conferred is low in most settings. Thus, to develop efﬁ-
ient subunit vaccines, screening and assessment of new protective
ntigens is essential.
Brucella is able to infect macrophages and to persist and replicate
n the intracellular environment [19]. Identifying those bacterial
roteins that are necessary for intracellular survival of Brucella
ay  provide new insights into mechanisms of pathogenesis and
mmune protection, and candidate antigens for vaccine design.
e previously described that sera from Rev.1-immunized rabbits
trongly reacted with the molecular chaperone DnaK of B. meliten-
is, which is also expressed in other strains [20]. The molecular
haperone DnaK (BMEI1549) is a member of the highly conserved
0-kilodalton heat-shock protein (hsp70) family [21]. Under stress
onditions, DnaK assists in protein folding, translocation and inter-
ction by binding to unfolded polypeptide domains [22]. However,
o data about the immunological properties of BMEI1549 product
as been reported yet. Importantly, the gene coding for this molec-
lar chaperone is different from the previously described Brucella
ene BMEI2002 that encodes a protein also designated DnaK. It was
hown that the latter confers a partial protection against Brucella
bortus infection in mice [23] and is necessary to resistant of Bru-
ella suis to bacterial killing of macrophages [24]. In the present
tudy, we evaluated for the ﬁrst time the immunogenicity and pro-
ective efﬁcacy of the puriﬁed recombinant DnaK (BMEI1549) in
ice. Protection against subsequent infection was evaluated after
accination with DnaK alone, or in combination two well-known
rotective antigens of B. melitensis recombinant outer membrane
rotein, Omp31 [20,25,26] and cytoplasmic protein, Trigger Factor
TF) [27–30]. We  hypothesized that inclusion of such antigens in
accine formulation could potentially augment the protective efﬁ-
acy of each antigen alone. With this in mind, the combination of
ifferent panel of antigens was tested in our experiments.
. Materials and methods
.1. Bacterial strains
E. coli TOP10 and BL21 (DE3) (a gift from Dr. Pourmand, Tehran
niversity of Medical Sciences) were used for expression of DnaK.
acterial strains were routinely grown at 37 ◦C in LB broth or agar.
. melitensis 16 M (virulent strain) or B. melitensis Rev.1 (vaccine
train) were cultured in Brucella agar (HiMedia, Delhi, India) as
escribed elsewhere [31].
.2. Production and puriﬁcation of DnaK
Cloning, expression, and puriﬁcation of DnaK from B. melitensis
n E. coli BL21 and its puriﬁcation have been described previously
20]. Brieﬂy, the dnak gene was ampliﬁed by PCR from genomic
NA of B. melitensis 16 M (Forward: 5′ CATATGACACCTT CTG 3′,
everse: 5′ GGATCCTACCGACCAGCG 3′). The ampliﬁed DNA frag-
ent was directly inserted into pTZ57R (InsTAcloneTM PCR Cloning
it) (Fermentas, Vilnius, Lithuania) and then subcloned into the
ET28a+ vector (Novagen, Madison, WI,  USA). 1 mM isopropyl--
-thiogalactopyranoside (IPTG) was used to induce expression of
naK. Puriﬁcation of DnaK was performed under denaturing condi-
ion as previously described [32]. Contaminating endotoxins were
liminated during the puriﬁcation step by 0.1% Triton X-114 in2 (2014) 6659–6666
washing buffers [33–35]. Vaccine protein should be in its native
form as far as effective blocking immune responses are concerned.
In our experiment we  ﬁrst solubilized the protein in 8 M urea for
the purpose of puriﬁcation and at the next step we re-folded the
protein in a stepwise dialyzing process with decreasing gradient of
urea. Finally puriﬁed protein was dialyzed against PBS.
2.3. The SDS-PAGE and Western blotting
The purity of the recombinant protein and its identity was
assessed by SDS-PAGE, Coomassie blue staining and Western blot-
ting [20]. Brieﬂy, puriﬁed recombinant protein was  size-separated
by SDS-PAGE and the proteins transferred to a nitrocellulose mem-
brane (BioRad, USA). Next, the membrane was incubated with
anti-6-His peroxidase (Roche, Mannheim, Germany) (1/40,000) for
1 h. Finally, the bound conjugates were detected using diaminoben-
zidine (DAB) (Sigma, NY, USA). Only puriﬁed recombinant protein
with an endotoxin content of less than 0.05 endotoxin units per
mg of protein (evaluated by Limulus amebocyte lysate analysis kit,
Lonza, Basel, Switzerland) was used. The concentration of recom-
binant protein was  determined by the Bradford method [36].
2.4. Mice
Six-to-eight weeks-old female BALB/c mice were purchased
from Pasteur Institute of Iran. Mice were handled under best possi-
ble conditions of temperature, hygiene, humidity and light (cycles
of 12 h dark/light). All experimental procedures on animals were
accepted by the ethical committee of Avicenna Research Institute.
After Rev.1 inoculation, mice were kept in biosafety level 3 animal
facilities.
2.5. Immunization
Mice were randomly divided into seven groups. Three groups
with 15 mice each received DnaK, PBS or Rev.1 vaccine only to
study immunogenicity and protective efﬁcacy. Two  groups includ-
ing 10 mice each received Omp31 and TF to assess lymphocyte
proliferation and conferred protection. The other groups consist-
ing of ﬁve mice each were used to evaluate and protection induced
by antigen cocktails. Mice were anaesthetized with methoxyfuor
ane (Mallinckrodt, Phillipsburg, NJ, USA) and immunized intraperi-
toneally (i.p.) either with 30 g of DnaK, TF or Omp31, 30 g
DnaK and 30 g TF [28], or 30 g DnaK and 30 g Omp31 [20],
or PBS (negative control) on day 0 and 15 as described previously
[23]. Brieﬂy, mice were injected with proteins or PBS in Complete
Freund’s Adjuvant (CFA) (Sigma) on day 0 and with incomplete Fre-
und’s adjuvant (IFA) (Sigma) on day 15. For comparison, a control
group was  immunized by the subcutaneous route (s.c.) at day 0
with 8 × 108 formalin-killed Rev.1 in IFA. Sera were obtained 0,
15, 30, and 45 days after the ﬁrst immunization. On day 45 after
the ﬁrst immunization, ﬁve mice from each group were challenged
intraperitoneally B. melitensis 16 M,  ﬁve mice were sacriﬁced to
assess immune responses including cytokine production and pro-
liferation assay, and the remaining ﬁve mice were bled on day 75
to monitor memory responses.
2.6. Humoral immune responses
The titers of DnaK-speciﬁc IgG1 and IgG2a antibodies in mouse
sera were investigated by ELISA as previously reported [20]. In order
to ﬁnd a cut-off value for this test, the mean speciﬁc OD plus 3
S.D. from 20 sera from PBS-immunized mice at 1:100 dilutions was
determined. Serum titers are denoted as the reciprocal of the last
serum dilution giving an OD higher than the cut-off [23].
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.7. Preparation and culture of splenocytes
Thirty days after the last immunization, spleens were removed
rom the mice immunized with DnaK, Omp31, TF, PBS or Rev.1 and
omogenized with a syringe in 10 ml  PBS containing 5 mM ethylene
iamine tetraacetic acid (PBS-EDTA) on ice. The cells were washed
wice with PBS-EDTA and mononuclear cells (MNCs) were isolated
y Ficoll–Paque (GE Healthcare, Uppsala, Sweden) discontinuous
radient centrifugation. The cells were cultured in RPMI 1640 based
edia (RPMI 1640 supplemented with 2 mM l-glutamine, 100 U/ml
enicillin, 100 g/ml streptomycin and 10% heat inactivated FBS)
t 37 ◦C in 5% CO2.
.8. Lymphocyte proliferation and cytokine assay
Mouse splenocytes were adjusted to 2 × 106 cells/ml and
00 l of this suspension were added per well of 96-well cul-
ure plates either alone (negative control), or together with
.25–1 g/ml of puriﬁed DnaK, Omp31, TF, or 3 g/ml of con-
anavalin A (Con A). The cells were cultured for 2 days and then
ncubated for 4 h with 100 l of 1 mg/ml  2,3-bis (2-methoxy-4-
itro-5-sulfophenyl)-5-((phenylamino) carbonyl)-2H-tetrazolium
ydroxide (XTT) (Sigma) containing 25 l of 5 mM phenazine
ethosulfate (PMS) (Sigma) per well as previously reported [8].
he optical density was read at 492 nm (Bio-Tek Instruments). The
timulation index (SI) was calculated as the ratio between the opti-
al density values of stimulated to unstimulated cells using the
ollowing formula:
I = mean OD of stimulated culture − mean OD of blank 
mean OD of unstimulated culture − mean OD of blank
To assess cytokine production, 2 × 106 splenocytes in 2 ml  of
omplete RPMI 1640 medium were brought out per well of a
4-well ﬂat-bottom plate. Cells were then incubated with 1 g/ml
naK or 3 g/ml Con A at 37 ◦C in 5% CO2 for 48 h [10]. Control
ells received PBS instead of antigen. Supernatants were col-
ected after 48 h and stored at −70 ◦C for cytokine assay. Levels
f interferon-gamma (IFN-), interleukins-(IL) 12 (p70), 10, 6, 5
nd 4 were measured according to the manufacturer’s instruc-
ions (BD Pharmingen). Minimal detection levels of the aforesaid
ytokine sets were 31.3 pg/ml, 62.5 pg/ml, 31.3 pg/ml, 15.6 pg/ml,
5.6 pg/ml, 7.8 pg/ml, respectively.
.9. Analysis of lymphocyte subtypes by ﬂow cytometry
Splenocytes (1 × 106 cells/ml) were stained with ﬂuorescein
sothiocyanate (FITC) labeled anti-mouse CD3, FITC labeled anti-
ouse CD4 and Phycoerythrin (PE) labeled anti-mouse CD8. FITC
nd PE-conjugated mouse IgG1 were used as isotype controls.
sing a Partec ﬂow cytometer (Partec PAS, Germany), lympho-
ytes were ﬁrst gated based on their forward and sideward scatters.
ata analysis was performed with FlowMax software (Partec PAS,
ermany).
.10. Protection experiments
Four weeks after the last immunization, ﬁve immunized mice
er group were challenged by i.p. injection of 0.2 ml  B. melitensis
6 M suspension containing 1 × 104 bacteria. Thirty days after bac-
erial challenge, mice were sacriﬁced and their spleens removed.
ach spleen was homogenized in 1 ml  0.9% NaCl containing 0.1%
riton X-100, serially diluted and plated on Brucella agar in tripli-
ates and incubated at 37 ◦C for 3–4 days [17,37]. The results were
xpressed as the mean log CFU ± S.D. per group.2 (2014) 6659–6666 6661
rol
trol
2.11. Statistical analysis
Data among several groups was  analyzed and compared by one
way one factor analysis of variance (ANOVA) and Turkey’s post hoc
test in SPSS. p values <0.05 were considered as statistically signiﬁ-
cant.
3. Results
3.1. Production of recombinant DnaK
In order to obtain large amounts of recombinant DnaK, E. coli was
transformed with the pET28-dnak plasmid and expression of the
6xhistidine-tagged protein induced with IPTG. Recombinant DnaK
was puriﬁed from bacterial lysates using Ni-NTA agarose. Identity
of the puriﬁed protein of 48 kDa as DnaK was veriﬁed by SDS-PAGE
and Western blotting (Fig. 1). Twenty mg  of the recombinant pro-
tein was obtained from 1 l of liquid culture.
3.2. Humoral responses induced by DnaK
Speciﬁc antibody titers against DnaK were measured by ELISA in
sera obtained at different days after the ﬁrst immunization of mice
with DnaK. DnaK-speciﬁc humoral responses became detectable
during the second week, peaked after six weeks, and maintained
at high levels until the eleventh week after the ﬁrst immuniza-
tion (Fig. 2). Throughout the entire observation period, although
not statistically signiﬁcant, IgG2a titers were consistently higher
than IgG1 titers (IgG1mean titer: 18,666; IgG2a mean titer: 20,
750). The mice vaccinated with Rev.1 also produced considerable
amounts of DnaK-speciﬁc IgG1 and IgG2a responses. However,
there was  a signiﬁcant difference between DnaK-speciﬁc IgG1 and
IgG2a titers elicited in the mice immunized with DnaK compared
to the amount of speciﬁc IgG1 and IgG2a against DnaK produced in
Rev.1-vaccinated mice, respectively (p < 0.001) (Fig. 2).
3.3. Cellular immune response
To further characterize the immune responses and, spleno-
cytes from mice immunized with DnaK, PBS, Omp31,TF or Rev.1
were isolated 45 days after the ﬁrst immunization, and incu-
bated with different concentrations of DnaK followed by analysis
of lymphocyte proliferation and cytokine production. In compar-
ison to PBS, speciﬁc proliferative responses were observed with
cells from DnaK- or Rev.1-vaccinated animals (Fig. 3). We  found
that splenocytes of DnaK-immunized mice were more responsive
to recall cognate antigen stimulation (0.25 g/ml) compared to
the TF-immunized mice. More speciﬁcally, in vitro proliferation
assay clearly showed that as low as 0.25 g/ml of DnaK induced
the same levels of antigen-speciﬁc proliferation compared to when
splenocytes from the TF-immunized mice were re-stimulated with
1 g/ml of TF antigens. Splenocytes from TF-immunized mice did
not show signiﬁcant proliferative response when stimulated with
0.25 g/ml cognate antigen (Fig. 3). Although splenocytes of Rev.
1-immunized mice did not proliferate in response to stimulation
with up to 2.5 g/ml TF, they responded to stimulation with TF in
concentrations more than 2.5 g/ml (data not shown). As positive
control, splenocytes of all groups proliferated in response to ConA
stimulation (data not shown).
6662 A. Ghasemi et al. / Vaccine 32 (2014) 6659–6666
Fig. 1. Conﬁrmation of cloning, expression and puriﬁcation of DnaK. (a) Digestion of pET-dnak with NdeI and BamHI  Lane 1: pET-28a+ digested with NdeI and BamHI  Lane
2:  pET-dnak digested with NdeI and BamHI, Lane 3: PCR product of dnak gene, Lan 4: molecular marker. (b) SDS-PAGE analysis of DnaK puriﬁcation. Lane 1: molecular weight
m h wit
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*arker,  Lane 2: after IPTG induction, Lane 3: ﬂow through, Lanes 4 and 5: the was
0  mM Imidazole, Lane 9: eluted recombinant protein with elution buffer containing
ane1:  puriﬁed DnaK, Lane 2: lysate of untransfected bacteria.
Lymphocytes from DnaK and Rev.1-vaccinated mice secreted
igniﬁcantly higher amounts of IFN-, IL-12 and IL-6 than PBS-
mmunized group (p < 0.001), which only produced background
evels of these cytokines. Such immunizations did not trigger
etectable levels of IL-4 production. DnaK induced very low lev-
ls of IL-10 and IL-5 production (Fig. 4). In response to ConA,
plenocytes from all groups produced IFN-, IL-12, IL-10, IL-5, and
L-4, with no signiﬁcant differences among the groups (data not
hown). In order to investigate the involvement of T cells in the
naK-speciﬁc immune responses, CD3+, CD4+ and CD8+ T lym-
hocyte in mouse spleens were analyzed by ﬂow cytometry. As
ig. 2. Kinetics of the IgG1 and IgG2a responses elicited after immunization with DnaK
ays.  Speciﬁc IgG1 and IgG2a antibody titers against DnaK were evaluated by ELISA. Tit
omparison of antigen-speciﬁc anti-DnaK IgG1 in DnaK-and Rev.1-immunized mice, com
** p < 0.001.h buffer containing 20 mM Imidazole, Lanes 6–8: the wash with buffer containing
midazole. (c) Western blot analysis of DnaK with anti-His tag monoclonal antibody.
shown in Fig. 5, the percentage of CD3+, CD4+ and CD8+ cells in the
DnaK-vaccinated group was signiﬁcantly increased in comparison
to PBS-immunized mice (p < 0.05).
3.4. Protection assay
To analyze the level of protection induced by DnaK in mice,
three groups of mice were immunized with DnaK, Rev.1, or PBS. In
addition, four other groups of mice received Omp31 or TF alone,
or in combination with DnaK. On day 45 after the ﬁrst immu-
nization, mice were challenged with 1 × 104 B. melitensis 16 M
. Mice were immunized with DnaK or Rev.1 and bled retroorbitally on the indicated
er values represent the mean ± SD of sera from ﬁve animals with three repeats. ‡
parison of antigen-speciﬁc anti-DnaK IgG2a in DnaK and Rev.1-immunized mice,
A. Ghasemi et al. / Vaccine 32 (2014) 6659–6666 6663
Table  1
Protection against B. melitensis infection conferred by DnaK immunization.
Immunized group (n = 5) Adjuvant Log10a CFU of Brucella melitensis Units of protectionb
PBS CFA/IFA 4.96 ± 0.42 0
DnaK  CFA/IFA 3.327 ± 0.38c 1.633
TF  CFA/IFA 2.75 ± 0.16c,d,e 2.2
Omp31 CFA/IFA 3.3 ± 0.29c 1.66
DnaK + TF CFA/IFA 3.12 ± 0.46c 1.84
DnaK + Omp31 CFA/IFA 3.08 ± 0.28c 1.88
Rev.1  IFA 2.78 ± 0.22c,d,f 2.18
a The bacteria content in spleens is represented as the mean log CFU ± S.D. per group.
b Units of protection were determined by deducting the mean log CFU of the immunized groups from the mean log CFU of the control (PBS-immunized) group.
c Signiﬁcantly different from PBS-immunized mice, p < 0.001.
d Signiﬁcantly different from Omp31, p < 0.05.
e Signiﬁcantly different from DnaK, p < 0.01.
f Signiﬁcantly different from DnaK, p < 0.05.
Fig. 3. Proliferative responses of spleen cells from mice immunized with DnaK. BALB/c mice were immunized with DnaK, Omp31, TF or Rev.1. Mice immunized with
PBS  were used as controls. Spleen cells from immunized mice were stimulated in vitro with 0.25–1 g/ml puriﬁed DnaK and 3 g/ml ConA for 48 h and the extent of
proliferation was  assayed by XTT. Each bar symbolizes the stimulation index (SI) computed as the ratio between the obtained mean absorbance values of stimulated cells to
the  unstimulated cells. The data are the mean SI ± SD of ﬁve individual mice from each group with three repeats. ‡ Comparison to PBS group and, comparison to Rev.1 group.
* p < 0.05; ** p < 0.01; *** p < 0.001.
Fig. 4. Cytokine production in spleen cells from mice immunized with PBS,
DnaK and Rev.1 vaccine. Spleen cells of PBS-, DnaK- or Rev.1-immunized mice were
stimulated in vitro with 1 g/ml DnaK for 48 h. Cytokine concentrations in culture
supernatants were measured by sandwich ELISA. The data are the mean ± SD of ﬁve
i ‡
a
Fig. 5. Analysis of T lymphocyte subsets in DnaK-vaccinated mice. Thirty days
after last immunization, splenocytes from BALB/c mice immunized with DnaK, Rev.1
or  PBS were collected and labeled with FITC-anti-mouse CD3, CD4 and PE-anti-
mouse CD8. Lymphocytes were gated based on forward and side scatter patternndividual mice from each group with two repeats. Comparison of DnaK to PBS
nd, comparison of Rev.1 to PBS group. ** p < 0.01; *** p < 0.001.
and the percentage of CD4 and CD8 cells were quantiﬁed using FlowMax software.
Each bar symbolizes the mean ± SD of the percentage of CD4+ or CD8+ T cells from
ﬁve individual mice with two repeats. Comparison of CD3 percent with PBS group,
‡ comparison of CD4 percent with PBS group,  comparison of CD8 percent with PBS
group * p < 0.05.
6 cine 3
l
r
t
t
a
D
t
H
v
O
t
c
p
b
p
4
t
v
i
f
L
i
i
T
b
a
p
p
f
t
a
[
p
t
m
s
n
c
i
i
P
R
p
l
w
h
i
a
t
t
t
P
i
a
M
c
g
l
c
e664 A. Ghasemi et al. / Vac
ive bacteria and protection was evaluated by measuring bacte-
ial colony forming units in the spleen of mice one month later. In
hese experiments, protection was deﬁned as a signiﬁcant reduc-
ion of splenic bacterial load as compared to mice injected with PBS
lone. The vaccine efﬁcacy was calculated as the log10 of protection.
naK-immunized mice exhibited a signiﬁcant degree of protec-
ion compared to control mice that had received PBS (p < 0.001).
owever, this protection was lower than that induced by the Rev.1
accine (p < 0.05) (Table 1). Of note, the combination of Dnak with
mp31 enhanced protection against infection in mice as compared
o DnaK or Omp31 alone, but this increase did not yet reach statisti-
al signiﬁcance. Although the level of protection conferred by DnaK
lus TF was higher than protection conferred in mice immunized
y DnaK alone, the immunization with DnaK plus TF did not exceed
rotection compared to TF alone (Table 1).
. Discussion
The identiﬁcation of immunodominant antigens is an impor-
ant step toward the development of safe and effective subunit
accines. In this regard, many studies on numerous cell surface and
ntracellular components of Brucella have been performed, but only
ew antigens have shown signiﬁcant protective potential including:
7/L12, Omp16, TF, Omp31, P39 and BLSOmp31 [10,18,27,38–41].
Immunity against Brucella is mainly mediated by mucosal
mmunity (MI) and acquired T cell-mediated immunity (CMI);
ncluding IFN- producing CD4+ T lymphocytes [42–44] and CD8+
 lymphocytes killing infected macrophages [45–47]. IFN- has
een shown to play a key role in the control of brucellosis by
ctivating macrophages and skewing antibody responses toward
rotective IgG2a [44]. We  hypothesized that abundantly expressed
roteins that are essential for infection might be good candidates
or subunit vaccines. Molecular chaperones such as DnaK are pro-
eins that assist in protein folding and prevent protein aggregation
nd thereby protect bacteria against conditions of cellular stress
48–50]. Consistent with this, immunization of mice with a DnaK
rotein from B. abortus has been shown previously to provide par-
ial protection against subsequent B. abortus infection [23]. The
olecular chaperon DnaK evaluated in this study, however, only
hares 12.5 percent identity with the DnaK protein from B. abortus.
Cell-mediated immune responses were assessed in mice vacci-
ated with DnaK by measuring antigen-speciﬁc proliferation and
ytokine production of splenocytes in vitro. Splenocytes from DnaK-
mmunized mice showed signiﬁcant levels of proliferation in vitro
n response to stimulation with DnaK (p < 0.001), compared to
BS-stimulated splenocytes. Of note, the proliferative response of
ev.1-vaccinated mice to1 g/ml DnaK was signiﬁcant higher com-
ared to control mice (p < 0.01), indicating that the attenuated
ive-vaccine elicited immune responses against DnaK.
The cytokines produced by splenocytes from vaccinated animals
ere predominantly of Th1 type (IL-12 and IFN-). In addition,
igh amounts of IL-6 were produced by splenocytes of DnaK-
mmunized mice. IL-6 involvement in innate and subsequently
daptive immune responses is that this cytokine is a key signal in
he transition from the initial innate immune response to infec-
ion to a more sustained adaptive immune response. Regarding
he fact the production of this cytokine is mainly triggered by the
AMP-mediated TLR signaling cascade and induces many favorable
mmune functions leading to pathogen elimination; it is conceiv-
ble that this cytokine serve a role in immunity against brucellosis.
oreover, IL-6 is one of the key determinants in causing naive T
ells to differentiate into Th17 cells, together with transforming
rowth factor (TGF)-.  Beside the role that IL-17 plays in control-
ing infection, this cytokine suppresses development of regulatory T
ells thereby induces favorable anti-infection immunity [51]. Inter-
stingly, it has been reported that Interleukin-6-deﬁcient mice are2 (2014) 6659–6666
highly susceptible to intracellular pathogen, Listeria monocytogenes
infection [52]. In this context, immnunogenic brucella antigens, like
DnaK, capable of inducing IL-6 production are desired.
To further investigate the Th1/Th2 proﬁle of the elicited immune
responses, production of antigen-speciﬁc IgG1 and IgG2a antibod-
ies was examined. Although recombinant DnaK induced humoral
immune responses predominantly of IgG2a isotype, comparable
IgG1 titers were also produced. There are other reports showing
that protective immune responses against Brucella vaccines are
associated with high levels of Th1 cytokines and high IgG2and
IgG1 levels [26,27,53–55]. Further recent examples include a
well-designed study conducted by Jain et al. [9] showing that
splenocytes from mice immunized with L9 based DNA vaccine
(pVaxL9) secreted Th1 type cytokines including IFN-, IL-2, TNF-
 but not IL-4 after re-stimulating with recombinant L9 in vitro
while immunization of mice with pVaxL9 elicited speciﬁc antibody
response of both IgG1 and IgG2a isotypes against L9. Another study
performed by Al-Maririet et al. [15] showed that immunization of
mice with E. coli BL21 (DE3) pEt15b-p39 with or without CpG ODN
induced IFN- but not IL-5 secretion in response to P39 antigen
in vitro while both IgG1 and IgG2a were elicited against P39. Why
do some antigens induce production of IgG1 in spite of no IL-4 or
IL-5 production? The reason for this phenomenon is not clear at
the moment but different kinetics of cytokine and antigen-speciﬁc
IgG1/2a production may  be one explanation.
In the spleen of DnaK-immunized mice, we  also observed a sig-
niﬁcant increase in the frequency of CD3+, CD4+ cells and a higher
CD4+/CD8+ cell ratio, implying an antigen-speciﬁc T cell activation
in vivo.
We next examined the protective capacity of DnaK vaccination
in a challenge assay of mouse model of brucellosis. Our results
showed that DnaK-immunized mice, although inferior to Rev.1
or TF vaccination, conferred protective immunity to mice. In our
point of view the level of protection is not the only determin-
ing factor in terms of superiority of one type of vaccine over the
other one. Interestingly, in vitro proliferation assay clearly showed
that as low as 0.25 g/ml of DnaK induced the same levels of
antigen-speciﬁc proliferation compared to when splenocytes from
TF-immunized mice were stimulated with 1 g/ml of TF antigens.
This implies that threshold level of bacterial load for infection
establishment is higher in DnaK-immunized mice in comparison
to the TF-immunized mice. In other words, DnaK-immunized mice
compared to TF-immunized mice are more likely to be resistant to
infection establishment when challenged with a low bacterial load.
Despite lower levels of cytokines and splenocyte proliferation
obtained in Rev.1 vaccine group compared with DnaK group, the
conferred protection was  much higher with Rev.1 vaccine. The
rational behind this ﬁnding is that splenocytes of all groups were
re-stimulated only with DnaK in vitro. In this regard it is imag-
inable that DnaK-immunized mice produced higher amounts of
cytokines and exhibited higher proliferation in response to immu-
nizing antigen than those that had been immunized with whole
bacteria containing multiple immunodominant antigens.
To investigate whether the protective capacity of DnaK is fur-
ther enhanced when combined with other antigens expressed at
different phases of the pathogen’s life cycle, mice were vaccinated
with DnaK in combination with two  well-known antigens, Omp31
[20] or TF [28].
Combination of DnaK and Omp31 induced a greater, but not sta-
tistically signiﬁcant, protection than the levels conferred by each
component alone. Notably, this combination, as opposed to each
component alone, induced statistically similar level of protection
as induced by Rev.1. Formulation of Brucella vaccines containing
two different components have been already tested with different
set of Brucella antigens. It has been reported that immunization of
mice with unlipidated Omp16 plus 19 formulated with IFA could
cine 3
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nhance the protection against B. abortus infection compared to sin-
le components although difference was not statistically signiﬁcant
18]. In another work conducted by Cassataro et al. [56], it has been
emonstrated that immunized mice with rBLS plus Omp3148–74
how an elevated protection against B. melitensis infection which
as at the same level as induced by Rev.1.
Although administration of DnaK plus TF caused an increase in
rotection as compared to DnaK alone, this combination unexpect-
dly protected less efﬁciently than TF alone (Table 1). In a similar
bservation, it has been reported that mice immunized simulta-
eously with DnaK and SurA didn’t show any synergic consequence
n protection compared to each component alone [23]. Why  the
ombination of different antigens may  have beneﬁcial or detrimen-
al effects on vaccine efﬁcacy is not well understood. Interestingly,
ocktail vaccines containing antigens that are expressed at differ-
nt phases of the pathogen’s life cycle may  show increased efﬁcacy
57] that is attributable to combination of DnaK with Omp31. In
ddition, interference of epitopes may  cause the lack of synergy
n vivo [18] which likely happened in combination of DnaK with TF.
n course of immune responses against a pathogenic microorgan-
sms containing multiple immunogenic determinants, most of the
mmune responses are usually focused against immunodominat
ne resulting to lower immune responses against subdominants
nes. Logistically, this can be viewed as an approach through which
ost concentrate its energy for an effective response. We  found
hat splenocytes of DnaK-immunized mice were more responsive
o recall cognate antigen stimulation compared to those of TF-
mmunized mice. This implies higher immunogenicity of DnaK
ompared to TF (although the level of protection was higher in TF-
mmunized mice). In this context it is conceivable that DnaK can
iminish or even mask the immune responses against TF which is
ess immunogenic.
In summary, our results show that DnaK is able to elicit cel-
ular responses of Th1-dominant type and to confer signiﬁcant
rotection against subsequent Brucella infection. Moreover, the
ombination of DnaK with Omp31 provided an increased protec-
ion compared to the administration of the single components.
uture studies shall address, which combinations of antigens are
ost effective. Ultimately, these studies may  lead to the devel-
pment of multivalent subunit vaccines that provide high level of
rotection against B. melitensis infection.
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